• LivaNova announced publication of full 36-month CORE-VNS study results in Neuromodulation, showing sustained benefits from VNS Therapy for drug-resistant epilepsy.
• Seizure reductions emerged early and improved over time in children and adults, with most responders maintaining or improving their outcomes.
• Treatment also improved quality of life and reduced seizure-related hospital use, with no new safety concerns identified.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Livanova plc published the original content used to generate this news brief via Business Wire (Ref. ID: 202610230900BIZWIRE_USPR_____20261023_BW479534) on October 23, 2026, and is solely responsible for the information contained therein.